ly3009120
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2013 (NCT02014116)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
BRAF inhibitor
- Serine/threonine-protein kinase RAFINHIBITOR
RAF1 inhibitor
ARAF inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNc1ncc2cc(-c3cc(NC(=O)NCCC(C)(C)C)c(F)cc3C)c(C)nc2n1- Mol. weight
- 424.52 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3577124 ↗
- ChEMBLCHEMBL3545195 ↗
Also known as
- dp-4978
- dp-4978
- ly3009120
- ly3009120
- ly-3009120
- ly-3009120
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02014116 | Phase 1 | Nov 26, 2013 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1